Cyclacel Pharmaceuticals (NASDAQ:CYCC – Get Free Report) and Cellectar Biosciences (NASDAQ:CLRB – Get Free Report) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their analyst recommendations, profitability, institutional ownership, risk, dividends, valuation and earnings.
Insider and Institutional Ownership
23.6% of Cyclacel Pharmaceuticals shares are held by institutional investors. Comparatively, 16.4% of Cellectar Biosciences shares are held by institutional investors. 24.0% of Cyclacel Pharmaceuticals shares are held by company insiders. Comparatively, 3.7% of Cellectar Biosciences shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
Risk and Volatility
Cyclacel Pharmaceuticals has a beta of 0.28, suggesting that its share price is 72% less volatile than the S&P 500. Comparatively, Cellectar Biosciences has a beta of 0.96, suggesting that its share price is 4% less volatile than the S&P 500.
Earnings & Valuation
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Cyclacel Pharmaceuticals | $74,000.00 | 25.98 | -$22.56 million | ($9.40) | -0.03 |
| Cellectar Biosciences | N/A | N/A | -$42.77 million | ($1.33) | -0.27 |
Cyclacel Pharmaceuticals has higher revenue and earnings than Cellectar Biosciences. Cellectar Biosciences is trading at a lower price-to-earnings ratio than Cyclacel Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Profitability
This table compares Cyclacel Pharmaceuticals and Cellectar Biosciences’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Cyclacel Pharmaceuticals | -18,150.00% | -1,901.11% | -188.23% |
| Cellectar Biosciences | N/A | N/A | -191.22% |
Analyst Ratings
This is a summary of recent ratings and recommmendations for Cyclacel Pharmaceuticals and Cellectar Biosciences, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Cyclacel Pharmaceuticals | 0 | 1 | 1 | 0 | 2.50 |
| Cellectar Biosciences | 0 | 1 | 1 | 0 | 2.50 |
Cyclacel Pharmaceuticals currently has a consensus price target of $11.00, indicating a potential upside of 3,497.12%. Cellectar Biosciences has a consensus price target of $12.50, indicating a potential upside of 3,370.29%. Given Cyclacel Pharmaceuticals’ higher probable upside, analysts clearly believe Cyclacel Pharmaceuticals is more favorable than Cellectar Biosciences.
Summary
Cyclacel Pharmaceuticals beats Cellectar Biosciences on 7 of the 11 factors compared between the two stocks.
About Cyclacel Pharmaceuticals
Cyclacel Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases in the United States, the United Kingdom, and internationally. The company's lead product includes fadraciclib, a cyclin dependent kinase Inhibitors (CDK) that is in Phase 1/2 clinical trial for the treatment of solid tumors and hematological malignancies, as well as in combination with venetoclax to treat relapsed or refractory chronic lymphocytic leukemia; and Plogosertib, a polo-like kinase inhibitor program, which is in Phase 1/2 clinical trial for the treatment of advanced solid tumors and hematological malignancies. It has a clinical collaboration agreement with the University of Texas MD Anderson Cancer Center to clinically evaluate the safety and efficacy of three cyclacel medicines in patients with hematological malignancies, including chronic lymphocytic leukemias, acute myeloid leukemias, myelodysplastic syndromes, and other advanced leukemias. The company was founded in 1996 and is headquartered in Berkeley Heights, New Jersey.
About Cellectar Biosciences
Cellectar Biosciences, Inc., a clinical biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of cancer. Its lead phospholipid drug conjugate (PDC) candidate is CLR 131 (iopofosine I-131), which is in Phase 2 clinical study for patients with B-cell malignancies; Phase 2a clinical study for patients with relapsed or refractory (r/r) Waldenstrom's macroglobulinemia cohort, r/r multiple myeloma (MM) cohort, and r/r non-Hodgkin's lymphoma cohort; Phase 1 clinical study for r/r pediatric patients with select solid tumors, lymphomas, and malignant brain tumors; and Phase 1 clinical study for r/r head and neck cancer. The company also develops CLR 1900, a PDC chemotherapeutic program that is in the preclinical development stage to treat solid tumors. It has collaborative with Orano Med to develop CLR 12120 Series; and LegoChemBio. The company was founded in 2002 and is headquartered in Florham Park, New Jersey.
Receive News & Ratings for Cyclacel Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cyclacel Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
